Glyphic Biotechnologies
Berkeley, US · 10 known investors
Glyphic Biotechnologies develops ProSE™, a high-throughput de novo protein sequencing technology for analyzing proteomes with single-molecule sensitivity. The platform serves research and therapeutic development in proteomics and drug discovery.
Investors · 10
Artis VenturesSan Francisco · $50K – $25M
Civilization Ventures Management, LlcTiburon · $1M – $10M
FoundersX VenturesSilicon Valley
LongeVCWashington D.C.
Modi VenturesHouston
WingPalo Alto · $200K – $20M
Axial VCreportedSan Francisco · $100K – $5M
Cantos VenturesreportedSan Francisco · $400K – $1.5M
FoundersX VenturesreportedCambridge
OMX VenturesreportedLincolnshire